Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...

CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

We’re in the midst of a paradigm shift in biomarker science. | The right biomarker signature can de-risk trials, guide ...

Chugai, a Japanese company majority owned by Roche, has identified Gero’s platform as complementary to its own capabilities.